Articles On Orthocell (ASX:OCC)

ASX climbs 0.48% in strong performance Nine of 11 sectors higher with 133/200 stocks climbing Most metals rally in solid commodity gain   Market powers higher in final hour The ASX 200 had a steady day of trade firmly above the line today...

Orthocell books a record quarterly revenue of $3.2 million for December quarter Revenue increased 7% in December compared to previous quarter and 45.2% over the pcp Seventh consecutive quarter of growth, achieving 10.4% compound quarterly...

Tylah Tully looks at the advancements Orthocell (ASX:OCC) have made over the past year and ahead to a 2026 which promises to have a scaling of its leading nerve repair treatment across the United States and more international markets.     T...

Highlights Janus Electric gains traction after key approval Mixed trading mood across broader market Company updates drive sector-specific interest The broader market eased while select companies drew attention through...

Orthocell Ltd (ASX: OCC) shares are having a good session on Tuesday. In morning trade, the small cap ASX share has risen 3% to $1.13. Why is this small cap ASX share charging higher? Investors have been buying the regenerative medicine com...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

Several ASX healthcare names secured US Food and Drug Administration approval in 2025, opening up the world’s largest healthcare market PainChek’s Adult App became first regulated device to assess pain in people who can’t reliably verbalis...

Highlights Resource updates signal growing project confidence Approvals and funding steps reshape development timelines Small-cap activity adds depth to local market sentiment Australian small-cap companies are advanci...

Orthocell submits application for approval of flagship nerve repair product Remplir in the UK and EU With ~500,000 surgical repairs of peripheral nerves annually in the region, market represents US$750 million opportunity Supported by real...

ASX trades sideways ahead of US Fed decision overnight Eight of 11 sectors down, weak breadth with 121/200 stocks falling Materials sector propped up by gold and silver prices   ASX trades sideways The ASX 200 is still in wait-and-see mod...

Orthocell achieves first commercial sales of Remplir in Hong Kong Sales mark a key milestone in Orthocell’s Asian growth strategy Remplir now selling in five major markets with two more expected in near term   Special Report: Orthocell ha...

Cogstate shares plunge on revenue and earnings downgrade Immuron shares have the runs after failed US military trial Was Immutep’s share price reaction underdone?   CogState (ASX:CGS) shares have tumbled as much as 30% on the back of a r...

Orthocell Ltd (ASX: OCC) shares are having a strong session on Wednesday. In morning trade, the ASX healthcare stock is up 7% to $1.09. Why is this ASX healthcare stock jumping? Investors have been buying the regenerative medicine company's...

John Van Der Wielen succeeds Neale Fong and adds to his chairmanships of the ASX-listed biotech Orthocell and the WA Government’s Future Health and Research Fund. 

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Host Tylah Tully chats with Orthocell (ASX:OCC) managing director and CEO Paul Anderson about the growing momentum behind Remplir, as surgeons find  a new indication for the company’s lead product. Most recently, the device has been adopted...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Company to invest in further research to strengthen clinical evidence ahead of mediu...

Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from...

Orthocell (ASX:OCC) has seen its share price jump on Thursday as the company unveils its latest early-stage successes observed in Australian prostate surgery patients who use nerve repair product Remplir. Listen to the HotCopper podcast...

Orthocell Ltd (ASX: OCC) shares are catching the eye on Thursday morning. At the time of writing, the ASX All Ords stock is up 7.5% to $1.08. Why is this ASX All Ords stock jumping? Investors have been buying the regenerative medicine compa...

Highlights Broad uptrend momentum seen across diverse sectors. Multiple companies experience renewed chart strength. Downtrend signals highlight shifting market sentiment. A comprehensive exploration of rising and weak...

Australian biotechs are carving out expanded territory in the US Truscreen edges towards cash flow break even CSL is extracting more blood from donors, more efficiently   Today’s crop of ASX announcements highlights the potential of the U...

ASX recovers from session lows of -0.91pc to fall -0.13pc Info tech, commodities weakness undercut market Banks, defensive sectors mount resistance ASX battens down the hatches It was looking like we were in for another 90-point routing...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Investors are stumping up cash for life sciences capital raisings – but the stories need to be well presented After an “incredibly tumultuous” nine months, fundraisings are on track to meet last year’s bumper tally of $2.9 billion Two medt...

ASX bounces off lows of -0.59pc to gain 0.15pc Info tech, banking stocks lead gains US-China trade truce undercuts critical mineral stocks   Westpac fuels banking wins The ASX 200 was set to notch a fifth day of losses before staging a la...

Poor Chinese relations, Covid, war and US tariffs prove too much for device maker Uscom The Mayne Health takeover deal isn’t over, but the prognosis is dire Bioxyne strikes medical cannabis vape import deal   Uscom bows out Uscom (ASX:UCM...

Big returns could be on the cards for buyers of Syrah Resources Ltd (ASX: SYR) shares. That's the view analysts at Macquarie Group Ltd (ASX: MQG), which are feeling very bullish about the ASX mining stock. What is the broker saying about th...

ASX falls to two-week lows, down 0.96pc Healthcare, industrials, financials smashed by high inflation read Uranium and resource stocks stage recovery   ASX tumbles on CPI read but uranium rallies Any chance of an intraday recovery was put...

Highlights Materials sector shows resilience in midday session Healthcare segment under performance pressure Key updates from Almonty Industries and Orthocell Materials stocks outperformed in midday trade a...

Orthocell appoints exclusive in-country distributor for flagship nerve-repair product Remplir in Hong Kong MontsMed is a highly credentialled medical device distribution company in Hong Kong First surgical cases and sales in Hong Kong expe...

Good Afternoon and welcome to HotCopper‘s Market Close, I’m Jon Davidson. It was a strong start to the week at least, ahead of Anthony Albanese and Trump’s meeting in Washington taking place tonight and in the early hours of Tuesday, as the...

Orthocell to increase its stake in fellow WA biotech Marine Biomedical from 1.7% to 12% through a $1 million investment A pivotal study on Marine’s Biomedical’s flagship product PearlBone nears completion to support US FDA approval Invest...

Orthocell (ASX:OCC) has boosted its stake in a Western Australia-based biotech company called ‘PearlBone,’ which uses nacre, the material from which pearls are made, but which also includes part of the shell, to create bone regeneration pro...

Botanix shares leap 17% on a solid start to the US rollout of the company’s anti-sweating treatment, Sofdra Radiopharm raises up to $40 million, while Orthocell banks $30 million Avita faces tough questions after surprise CEO departure B...

ASX falls 73 points, sliding back below 9000 points Only three sectors marginally higher, XGD up 1.27pc Defence-related, energy and info tech stocks tumble   The ASX 200 couldn’t maintain much of its gains this week, giving up the fight j...

Let’s dive into what HotCopper users have been tracking on Friday in what has been a fairly jarring day for many – but perhaps not for those who took profits on Thursday. Listen to the HotCopper podcast for in-depth discussions and insi...

The ASX health sector moved up 1.30% for the week, while the broader market inched up 0.12% Aroa recorded fourth consecutive quarter of positive net cash flow with Myriad breaking records Orthocell raised $30 million in oversubscribed plac...

Orthocell Ltd (ASX: OCC) shares are on course to end the week in the red. In morning trade, the ASX stock is down 7% to $1.33. However, longer term shareholders won't be too downbeat. That's because the regenerative medicine company's share...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Another volatile session on Wall Street, as US/China trade concerns lingered, but th...

ASX closes up 1.03% to four-day high with strong performances in healthcare, materials and financials Gold hits another all-time high – of US$4211 per ounce Telix surges 16% after reporting robust September quarter revenue from its prostat...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

The funds will also support the purchase of a 15 per cent stake in fellow WA biotech, the unlisted Marine Biomedical, and a clinical study into the use of Remplir in prostate cancer surgery.

Netwealth Group Ltd (ASX: NWL) shares tumbled 4% yesterday, finishing Monday's trading at $31.21.  Despite the drop, Netwealth shares remain up almost 14% over the last year.  Netwealth is a financial services and technology company....

With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading...

The S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. At the time of writing, the benchmark index is down 0.7% to 8,898.4 points. Four ASX shares that are not letting that hold them back are lis...

The Australian share market has traditionally delivered a return of approximately 10% per annum. But investors may not have to settle for that when analysts at Morgans are expecting even greater returns for the ASX 200 shares named below. L...

Regenerative medicine is a fast-growing healthcare field that harnesses the body’s natural healing ability At Monash University, the Australian Regenerative Medicine Institute is internationally recognised for pioneering research Several A...

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

Now could be a good time to pounce on the ASX 200 stock in this article. That's the view of analysts at Bell Potter, which believe that market-beating returns could be on the cards for investors over the next 12 months. Which ASX 200 stock?...